United Therapeutics Cash Flow Statement
UTHR / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
United Therapeutics generated $1.6B in operating cash flow and $1.0B in free cash flow in FY2025. Free cash flow margin was 32.7% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.3B | $1.2B | $984.8M | $727.3M | $475.8M | - | -$104.5M | $589.2M | $651.6M | $713.7M | $651.6M | - | - | - | - |
| Depreciation & Amortization | $85.6M | $72.5M | $53.2M | $51.3M | $49.9M | $49.9M | $45.9M | $35.9M | $32.9M | $31.6M | $32.9M | $32.2M | $31.3M | $17.9M | $11.4M |
| Operating Cash Flow | $1.6B | $1.3B | $978.0M | $802.5M | $598.2M | $755.7M | -$206.6M | $778.4M | $382.8M | $643.6M | $382.8M | $355.3M | $425.3M | $211.5M | $99.7M |
| Capital Expenditures | $520.5M | $246.5M | $230.4M | $138.8M | $120.8M | $59.3M | $83.7M | $184.4M | $49.8M | $38.0M | $49.8M | $47.4M | $31.9M | $18.6M | $95.4M |
| Free Cash Flow | $1.0B | $1.1B | $747.6M | $663.7M | $477.4M | $696.4M | -$290.3M | $594.0M | $333.0M | $605.6M | $333.0M | $307.9M | $393.4M | $192.9M | $4.3M |
| Share Buybacks | $1.0B | $1.0B | $0 | $0 | - | - | - | - | $394.5M | $500.0M | $394.5M | $483.1M | $42.4M | $212.0M | $212.0M |
| FCF Margin | 32.7% | 37.5% | 32.1% | 34.3% | 28.3% | 46.9% | -20.0% | 36.5% | 22.7% | 37.9% | 22.7% | 23.9% | 35.2% | 32.5% | 1.2% |